Nanomix Registers New POC System in the United Kingdom

Nanomix Corporation has officially registered its eLab system and S1 Panel Catridge.

“This registration is an important step in accelerating the introduction and availability of Nanomix products to markets and patients throughout the United Kingdom. The S1 Panel provides multiple test results from a single patient sample and a single cartridge in less than 11 minutes. Timely diagnostics, by the bedside, are targeted to improve treatment and transition of care decisions in both Point-of-Care and Hospital settings,” said John Hardesky, chief commercial officer of Nanomix.
 
The Nanomix eLab analyzer with S1 Panel Cartridge provides multiple host-response biomarker results that can diagnose critical infections in patients, including sepsis. The Nanomix eLab is a mobile, hand-held immunoassay and chemistry diagnostic system. The Nanomix eLab offers the benefits of results in minutes, low cost, and portability while providing accurate, quantitative results comparable in quality to those provided by central lab testing.
 
The Nanomix eLab S1 Panel Cartridge is a wholly contained, disposable cartridge technology containing reagents and biosensors that provide quantitative measurement of two biomarkers, C-reactive protein (CRP) and Procalcitonin (PCT) and the metabolite Lactate (LAC), each of which may be used in the evaluation of critical infections. The product provides sample-to-answer results that can be used by healthcare providers to aid decision making on antibiotic therapy for patients with suspected or confirmed sepsis and/or suspected or confirmed lower respiratory tract infections (LRTI) defined as community acquired pneumonia (CAP) acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in an inpatient setting or Emergency Department.
 
The Nanomix eLab S1 Panel Cartridge has received CE Mark and MHRA Registration.
 
Nanomix develops mobile point-of-care diagnostics with its Nanomix eLab platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. Nanomix’s first assay addresses the critical need for faster diagnosis of critical infections. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes.